ACSL4 and COVID-19: Pioglitazone and Troglitazone, two FDA-approved thiazolidinediones for diabetes, can reduce cell ferroptosis and viral replication by selectively inhibiting ACSL4 activity during SARS-CoV-2 infection.264,265 Two randomized phase IV clinical trials of pioglitazone utilized in patients with COVID-19 concurrently with type 2 diabetes are recruiting (NCT04604223 and NCT04535700).